LitAlert ~~ GeneLit.com

    • Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes.
    • Gu L, Mehta PP, Rao D, Rotemberg V, Capanu M, Chou J, Lin S, Sigel CS, Busam KJ, Boyce L, Gordon A, O'Reilly EM.
    • Cancer Med. 2022 Jun 6. doi: 10.1002/cam4.4916. Epub ahead of print.
    • Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    • Sa JK, Kim J, Kang S, Kim SW, Song T, Shim SH, Choi MC, No JH, Song JY, Kim D, Kim YM, Kim JH, Lee JW.
    • Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34150. Epub ahead of print.
    • BRCA1/2 pathogenetic variant carriers and reproductive decisions: Gender differences and factors associated with the choice of preimplantation genetic diagnosis (PGD) and prenatal diagnosis (PND).
    • Lombardi L, Trumello C, Stuppia L, Antonucci I, Brandão T, Babore A.
    • J Assist Reprod Genet. 2022 Jun 4. doi: 10.1007/s10815-022-02523-y. Epub ahead of print.
    • Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK).
    • Loong L, Garrett A, Allen S, Choi S, Durkie M, Callaway A, Drummond J, Burghel GJ, Robinson R, Torr B, Berry IR, Wallace AJ, Eccles DM, Ellard S, Baple E, Evans DG, Woodward ER, Kulkarni A, Lalloo F, Tischkowitz M, Lucassen A, Hanson H, Turnbull C; CanVIG-UK.
    • Genet Med. 2022 Jun 3:S1098-3600(22)00757-2. doi: 10.1016/j.gim.2022.05.002. Epub ahead of print.
    • An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance.
    • Iversen ES Jr, Lipton G, Hart SN, Lee KY, Hu C, Polley EC, Pesaran T, Yussuf A, LaDuca H, Chao E, Karam R, Goldgar DE, Couch FJ, Monteiro ANA.
    • NPJ Genom Med. 2022 Jun 3;7(1):35. doi: 10.1038/s41525-022-00302-3.
    • Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    • Meijer TG, Nguyen L, Van Hoeck A, Sieuwerts AM, Verkaik NS, Ladan MM, Ruigrok-Ritstier K, van Deurzen CHM, van de Werken HJG, Lips EH, Linn SC, Memari Y, Davies H, Nik-Zainal S, Kanaar R, Martens JWM, Cuppen E, Jager A, van Gent DC.
    • Oncogene. 2022 Jun 3. doi: 10.1038/s41388-022-02363-1. Epub ahead of print.
    • Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
    • Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium, Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F.
    • NAR Cancer. 2022 May 27;4(2):zcac016. doi: 10.1093/narcan/zcac016.
    • How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world.
    • Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E.
    • World J Clin Oncol. 2022 May 24;13(5):417-422. doi: 10.5306/wjco.v13.i5.417.